This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Usmani, Saad
| Item Type | Name |
|
Concept
|
Drug Administration Schedule
|
|
Concept
|
Administration, Cutaneous
|
|
Concept
|
Drug Administration Routes
|
|
Academic Article
|
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
|
|
Academic Article
|
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
|
|
Academic Article
|
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
|
|
Academic Article
|
Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses.
|
|
Academic Article
|
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.
|
|
Academic Article
|
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
|
|
Academic Article
|
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
|
|
Academic Article
|
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
|
|
Academic Article
|
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
|
|
Academic Article
|
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
|
|
Academic Article
|
An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma.
|
|
Academic Article
|
Subcutaneous versus intravenous daratumumab in multiple myeloma - Authors' reply.
|
|
Academic Article
|
Daratumumab subcutaneous formulation for the treatment of multiple myeloma.
|
|
Academic Article
|
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.
|
|
Academic Article
|
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
|
|
Academic Article
|
Teclistamab, a B-cell maturation antigen???CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
|
|
Concept
|
Administration, Metronomic
|
|
Concept
|
Administration, Intravenous
|
|
Academic Article
|
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
|
- Organization and Administration